BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 36943661)

  • 1. Direct oral anticoagulants in patients with venous thromboembolism and hematological malignancies.
    Robinson R; Spectre G; Lishner M; Sharabi O; Robinson E; Hamburger Avnery O; Gafter-Gvili A; Raanani P; Leader A
    J Thromb Thrombolysis; 2023 May; 55(4):729-736. PubMed ID: 36943661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial.
    Schrag D; Uno H; Rosovsky R; Rutherford C; Sanfilippo K; Villano JL; Drescher M; Jayaram N; Holmes C; Feldman L; Zattra O; Farrar-Muir H; Cronin C; Basch E; Weiss A; Connors JM;
    JAMA; 2023 Jun; 329(22):1924-1933. PubMed ID: 37266947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies.
    Guan T; Laguna A; Soares A; Legasto CS; Block S; Saunders IM; Alvarez K; Pon T; Patel N; Mahajan A; Lee A
    J Thromb Thrombolysis; 2023 Oct; 56(3):439-446. PubMed ID: 37421494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors.
    Lee A; Oley F; Lo M; Fong R; McGann M; Saunders I; Block S; Mahajan A; Pon TK
    Thromb Res; 2021 Dec; 208():148-155. PubMed ID: 34798446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants.
    Posch F; Königsbrügge O; Zielinski C; Pabinger I; Ay C
    Thromb Res; 2015 Sep; 136(3):582-9. PubMed ID: 26210891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: A retrospective cohort study.
    Reed-Guy L; Desai AS; Phillips RE; Croteau D; Albright K; O'Neill M; Brem S; O'Rourke DM; Amankulor NM; Bagley SJ
    Neuro Oncol; 2022 Dec; 24(12):2172-2179. PubMed ID: 35551405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
    Pernod G; Joly M; Sonnet B
    J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
    Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
    JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies.
    Swartz AW; Drappatz J
    Oncologist; 2021 May; 26(5):427-432. PubMed ID: 33523555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.
    Ross JA; Miller MM; Rojas Hernandez CM
    Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study.
    Bang SM; Kang JH; Hong MH; Ahn JS; Oh SY; Baek JH; Choi YJ; Shin SH; Kim YJ; Gil HY; Park HE; Lee J; Park EL
    Clin Appl Thromb Hemost; 2021; 27():1076029620979575. PubMed ID: 33471574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism.
    Zakai NA; Walker RF; MacLehose RF; Adam TJ; Alonso A; Lutsey PL
    J Thromb Haemost; 2018 Dec; 16(12):2403-2412. PubMed ID: 30240508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased Bleeding Incidence with Direct Oral Anticoagulants Compared to Vitamin K Antagonist and Low-Molecular-Weight Heparin in Patients with Sickle Cell Disease and Venous Thromboembolism.
    Patel A; Williams H; Baer MR; Zimrin AB; Law JY
    Acta Haematol; 2019; 142(4):233-238. PubMed ID: 31108496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of direct oral anticoagulants in patients with cancer associated venous thromboembolism.
    Douros A; Filliter C; Azoulay L; Tagalakis V
    Thromb Res; 2021 Jun; 202():128-133. PubMed ID: 33836492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis.
    Giustozzi M; Agnelli G; Del Toro-Cervera J; Klok FA; Rosovsky RP; Martin AC; Herold J; Tzoran I; Szmit S; Bertoletti L; Becattini C; Huisman MV
    Thromb Haemost; 2020 Jul; 120(7):1128-1136. PubMed ID: 32365386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma.
    Shayeb AM; McManus HD; Urman D; Jani C; Zhang T; Dizman N; Meza L; Sivakumar A; Gan CL; Barata P; Bilen MA; Gao X; Heng D; Pal S; Narra R; Kilari D; Kaymakcalan MD; McGregor B; Choueiri TK; McKay RR
    Clin Genitourin Cancer; 2023 Feb; 21(1):55-62. PubMed ID: 36411184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors.
    Carney BJ; Uhlmann EJ; Puligandla M; Mantia C; Weber GM; Neuberg DS; Zwicker JI
    J Thromb Haemost; 2019 Jan; 17(1):72-76. PubMed ID: 30450803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
    O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
    Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effectiveness of Anticoagulants in Patients With Cancer-Associated Thrombosis.
    Riaz IB; Fuentes H; Deng Y; Naqvi SAA; Yao X; Sangaralingham LR; Houghton DE; Padrnos LJ; Shamoun FE; Wysokinski WE; McBane RD
    JAMA Netw Open; 2023 Jul; 6(7):e2325283. PubMed ID: 37486628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis.
    Dawwas GK; Dietrich E; Smith SM; Davis K; Park H
    Clin Ther; 2020 Sep; 42(9):e161-e176. PubMed ID: 32768247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.